Bg pattern

SMOFKABIVEN LOW OSMO PERIPHERAL EMULSION FOR INFUSION

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use SMOFKABIVEN LOW OSMO PERIPHERAL EMULSION FOR INFUSION

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the User

SmofKabiven Low Osmo Periférico emulsion for infusion

Read all of this leaflet carefully before you start using this medicine because it contains important information for you

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist, or nurse.
  • If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack:

  1. What SmofKabiven Low Osmo Periférico is and what it is used for
  2. What you need to know before you use SmofKabiven Low Osmo Periférico
  3. How to use SmofKabiven Low Osmo Periférico
  4. Possible side effects
  5. Storage of SmofKabiven Low Osmo Periférico
  6. Contents of the pack and other information

1. What SmofKabiven Low Osmo Periférico is and what it is used for

SmofKabiven Low Osmo Periférico is an emulsion for infusion that is administered into your blood through a drip (intravenous infusion). The product contains amino acids (components used in the formation of proteins), glucose (carbohydrates), lipids (fat), and salts (electrolytes), in a plastic bag and can be administered to adults and children from 2 years of age.

A healthcare professional will administer SmofKabiven Low Osmo Periférico when other forms of nutrition are not sufficient or not possible.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you use SmofKabiven Low Osmo Periférico

Do not use SmofKabiven Low Osmo Periférico:

  • if you are allergic (hypersensitive) to the active substances or to any of the other components of this medicine (listed in section 6)
  • if you are allergic to fish or egg
  • if you are allergic to peanuts or soy, you should not use this product. SmofKabiven Low Osmo Periférico contains soybean oil
  • if you have too much fat in your blood (hyperlipidemia)
  • if you have severe liver impairment
  • if you have blood coagulation problems (coagulation disorders)
  • if your body has problems using amino acids
  • if you have severe kidney disease without the possibility of dialysis
  • if you are in acute shock
  • if you have too much sugar in your blood (hyperglycemia) that is not controlled
  • if you have high levels of salts (electrolytes) in your blood (serum) included in SmofKabiven Low Osmo Periférico
  • if you have fluid in your lungs (acute pulmonary edema)
  • if you have too much fluid in your body (overhydration)
  • if you have untreated heart failure
  • if you have a defect in your blood coagulation system (hemophagocytic syndrome)
  • if you are in an unstable situation, such as after severe trauma, uncontrolled diabetes mellitus, acute heart attack, stroke, blood clot, metabolic acidosis (a condition that leads to too much acid in your blood), severe infection (sepsis), coma, and if you do not have enough fluid in your body (hypotonic dehydration)
  • in newborn babies or children under 2 years of age

Warnings and precautions

Consult your doctor before starting to use SmofKabiven Low Osmo Periférico if you have:

  • kidney problems
  • diabetes mellitus
  • pancreatitis (inflammation of the pancreas)
  • liver problems
  • hypothyroidism (thyroid problems)
  • sepsis (severe infection)

If during infusion you experience fever, rash, swelling, difficulty breathing, chills, sweating, nausea, or vomiting, inform your healthcare professional immediately, as these symptoms could be caused by an allergic reaction or because you are receiving too much of the medicine.

Your doctor will need to regularly check your blood through liver function tests and other values.

Children and adolescents

SmofKabiven Low Osmo Periférico is not intended for newborn babies or children under 2 years of age. SmofKabiven Low Osmo Periférico can be administered to children from 2 to 18 years of age.

Using SmofKabiven Low Osmo Periférico with other medicines

Tell your doctor if you are taking, have recently taken, or might take any other medicines, including those obtained without a prescription.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor before using this medicine.

There is no information on the use of SmofKabiven Low Osmo Periférico during pregnancy. SmofKabiven Low Osmo Periférico should only be administered to pregnant women if the doctor considers it absolutely necessary. The use of SmofKabiven Low Osmo Periférico may be considered during pregnancy if your doctor advises it.

No data are available on exposure in breastfeeding women.

The components and metabolites of parenteral nutrition such as SmofKabiven Low Osmo Periférico are excreted in human milk. Parenteral nutrition may be necessary during breastfeeding. SmofKabiven Low Osmo Periférico should only be administered to breastfeeding women when the doctor has weighed the potential risks and benefits.

Driving and using machines

This is not relevant, as this medicine is administered in the hospital.

3. How to use SmofKabiven Low Osmo Periférico

Follow exactly the administration instructions of this medicine given by your doctor. In case of doubt, consult your doctor again.

Your doctor will decide the dose for you individually depending on your body weight and situation. SmofKabiven Low Osmo Periférico will be administered by a healthcare professional.

If you use more SmofKabiven Low Osmo Periférico than you should

It is very unlikely that you will receive too much of the medicine, as SmofKabiven Low Osmo Periférico will be administered by a healthcare professional.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Common(may affect up to 1 in 10 people): a slight increase in body temperature, inflammation in peripheral veins in connection with the injection site.

Uncommon(may affect up to 1 in 100 people): high levels of liver components in the blood (plasma), loss of appetite, nausea, vomiting, chills, dizziness, and headache.

Rare(may affect up to 1 in 1000 people): low or high blood pressure, difficulty breathing, rapid heart rate (tachycardia). Hypersensitivity reactions (which can cause symptoms such as swelling, fever, drop in blood pressure, skin rash, hives, redness, headache). Sensations of cold and heat. Paleness. Blue discoloration of the lips and skin (due to lack of oxygen in the blood). Pain in the neck, back, bones, chest, and lumbar region.

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if it is possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of SmofKabiven Low Osmo Periférico

Keep this medicine out of the sight and reach of children.

Store in the outer bag. Do not store above 25°C. Do not freeze.

Do not use this medicine after the expiry date which is stated on the label of the bag and the carton. The expiry date is the last day of the month stated.

6. Container Contents and Additional Information

SmofKabiven Low Osmo Peripherally contains

The active substances are

g per 1,000 ml

Glucose (as monohydrate)

68

Alanine

3.5

Arginine

3.0

Glycine

2.8

Histidine

0.75

Isoleucine

1.3

Leucine

1.9

Lysine (as acetate)

1.7

Methionine

1.1

Phenylalanine

1.3

Proline

2.8

Serine

1.6

Taurine

0.25

Threonine

1.1

Tryptophan

0.50

Tyrosine

0.10

Valine

1.6

Calcium chloride (as dihydrate)

0.14

Sodium glycerophosphate (as hydrate)

1.0

Magnesium sulfate (as heptahydrate)

0.30

Potassium chloride

1.1

Sodium acetate (as trihydrate)

0.85

Zinc sulfate (as heptahydrate)

0.0032

Refined soybean oil

11

Medium-chain triglycerides

11

Refined olive oil

8.8

Fish oil rich in omega-3 fatty acids

5.3

The other components are: glycerol, purified egg phospholipids, all-rac-α-tocopherol, sodium hydroxide (pH adjustment), sodium oleate, glacial acetic acid (pH adjustment), and water for injectable preparations.

Appearance of the Product and Container Contents

The glucose and amino acid solutions are transparent, colorless, or slightly yellow and free of particles. The lipid emulsion is white and homogeneous.

Container Sizes:

1 x 850 ml, 5 x 850 ml

1 x 1,400 ml, 4 x 1,400 ml

1 x 1,950 ml, 4 x 1,950 ml

1 x 2,500 ml, 3 x 2,500 ml

Marketing Authorization Holder and Manufacturer

Marketing Authorization Holder

Fresenius Kabi España S.A.U.

C/ Marina 16-18.

08005 Barcelona (Spain)

Manufacturer

Fresenius Kabi AB, SE-751 74 Uppsala, Sweden

This Medicinal Product is Authorized in the Member States of the European Economic Area under the Following Names:

Member State Name

Medicinal Product Name

Austria

SmofKabiven Low Osmo peripher Emulsion zur Infusion

Belgium

SmofKabiven Low Osmo Perifeer Smofkabiven Low Osmo Périphérique SmofKabiven Low Osmo Peripher

Bulgaria

??????????? ??? ???? ????????? ?????????? ???????

Croatia

SmofKabiven Low Osmo Peripheral

Cyprus

SmofKabiven Low Osmo Peripheral

Czech Rep.

SmofKabiven Low Osmo Peripheral

Denmark

SmofKabiven Low Osmo Peripheral

Estonia

SmofKabiven Low Osmo Peripheral

Finland

SmofKabiven Low Osmo Peripheral

Germany

SmofKabiven Low Osmo peripher Emulsion zur Infusion

Greece

SmofKabiven Low Osmo Peripheral

Hungary

SmofKabiven Low Osmo Peripheral

Iceland

SmofKabiven Low Osmo Peripheral

Ireland

SmofKabiven Low Osmo Peripheral

Latvia

SmofKabiven Low Osmo Peripheral

Lithuania

SmofKabiven Low Osmo Peripheral

Luxembourg

SmofKabiven Low Osmo peripher Emulsion zur Infusion

Netherlands

SmofKabiven Low Osmo Perifeer

Norway

SmofKabiven Low Osmo Peripheral

Poland

SmofKabiven Low Osmo Peripheral

Portugal

SmofKabiven Low Osmo Peripheral

Romania

SmofKabiven Low Osmo Peripheral emulsie perfuzabila

Slovakia

SmofKabiven Low Osmo Peripheral

Slovenia

SmofKabiven Peripheral Low Osmo emulzija za infundiranje

Spain

SmofKabiven Low Osmo Periférico.

Sweden

SmofKabiven Low Osmo Peripheral

United Kingdom

SmofKabiven Low Osmo Peripheral

Date of the Last Revision of this Leaflet: July 2023

Detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/

------------------------------------------------------------------------------------------------------------------

This information is intended only for healthcare professionals:

Special Warnings and Precautions for Use

To avoid the risks associated with too rapid infusion rates, it is recommended to use continuous and well-controlled infusion, if possible using an infusion pump.

Since the use of a peripheral vein is associated with a high risk of infection, strict aseptic precautions should be taken to avoid any contamination during catheter insertion and handling.

Serum glucose, electrolytes, and osmolarity, as well as fluid balance, acid-base balance, and liver enzyme levels, should be monitored.

Upon any sign or symptom of anaphylactic reaction (such as fever, shivering, skin rash, or dyspnea), the infusion should be immediately discontinued.

SmofKabiven Low Osmo Peripherally should not be administered simultaneously with blood in the same infusion equipment due to the risk of pseudoagglutination.

Thrombophlebitis may occur if peripheral veins are used for infusion. The catheter insertion site should be checked daily for local signs of thrombophlebitis.

Method of Administration

Intravenous route, infusion in a peripheral or central vein.

To provide complete parenteral nutrition, oligoelements, vitamins, and possibly electrolytes (taking into account the electrolytes already present in SmofKabiven Low Osmo Peripherally) should be added to SmofKabiven Low Osmo Peripherally, according to the patient's needs.

Posology

Adults

Dosage:

The dose range of 20 ml - 40 ml of SmofKabiven Low Osmo Peripherally /kg body weight/day corresponds to 0.08-0.16 g nitrogen/kg body weight/day (0.5-1.0 g amino acids/kg body weight/day) and 14-29 kcal/kg body weight/day of total energy (12-25 kcal/kg body weight/day of non-protein energy).

Infusion Rate

The maximum infusion rate for glucose is 0.25 g/kg body weight/h, for amino acids 0.1 g/kg body weight/h, and for lipids 0.15 g/kg body weight/h.

The infusion rate should not exceed 3.7 ml/kg body weight/hour (corresponding to 0.25 g glucose, 0.09 g amino acids, and 0.13 g lipids/kg body weight/h). The recommended infusion period is 12-24 hours.

Maximum Daily Dose

The maximum daily dose varies with the patient's clinical situation and may even change from day to day. The recommended maximum daily dose is 40 ml/kg body weight/day.

Pediatric Population

Children (2-11 years)

Dosage:

The dose of up to 40 ml/kg body weight/day should be adjusted regularly according to the pediatric patient's requirements, which vary more than in adult patients.

Infusion Rate:

The maximum recommended infusion rate is 4.0 ml/kg body weight/h (corresponding to 0.10 g amino acids /kg/h, 0.27 g glucose/kg/h, and 0.14 g lipids/kg/h). At the maximum recommended infusion rate, infusion periods greater than 10 hours should not be used, except in exceptional cases and under close monitoring.

The recommended infusion period is 12-24 hours.

Maximum Daily Dose:

The maximum daily dose varies with the patient's clinical condition and may even change from day to day. The maximum daily dose is 40 ml/kg body weight/day.

Adolescents (12-18 years)

SmofKabiven Low Osmo Peripherally can be used in adolescents in the same way as in adults.

Disposal Precautions

Do not use if the container is damaged.

Use only if the amino acid and glucose solutions are transparent and colorless or slightly yellow, and if the lipid emulsion is white and homogeneous. The contents of the three separate chambers should be mixed before use and before making any additions through the additive port. After opening the peel-type seals, the bag should be inverted several times to ensure a homogeneous mixture, which does not show evidence of phase separation.

For single use. Any remaining mixture should be discarded after infusion.

Compatibility

Compatibility data are available for the products Dipeptiven, Supliven, Vitalipid Adults, Soluvit (lyophilized), and Glycophos in defined quantities and generic sodium or potassium solutions in defined concentrations. When adding sodium, potassium, or phosphate, the amounts already present in the bag should be taken into account according to the patient's clinical needs. The generated data support additions to the activated bag according to the following table:

Volume

SmofKabiven Low Osmo Peripherally

850 ml, 1,400 ml, 1,950 ml, and 2,500 ml

Additive

Dipeptiven

0 - 300 ml

Supliven

0 - 10 ml

Soluvit (lyophilized)

0 - 1 vial

Vitalipid Adults

0 - 10 ml

Electrolyte Interval*

Sodium

≤ 150 mmol/l

Potassium

≤ 150 mmol/l

Phosphate (Glycophos)

≤ 15 mmol/l

  • Including the amounts present in the bag

Note: This table indicates compatibility. It is not a dosage guideline.

Additions should be made aseptically.

Validity Period after Mixing

The physical and chemical stability of the mixed three-chamber bag has been demonstrated for 36 hours at 25°C. From a microbiological point of view, the product should be used immediately. If not used immediately, the storage time before use and storage conditions are the responsibility of the user and should not normally exceed 24 hours at 2-8°C.

Validity Period after Mixing with Additives

From a microbiological point of view, the product should be used immediately after making additions. If not used immediately, the storage time before use and storage conditions are the responsibility of the user. The storage time should not normally exceed 24 hours at 2-8°C.

Instructions for the Use of SmofKabiven Low Osmo Peripherally

The Bag

850 ml, 1,400 ml, 1,950 ml, 2,500 ml

Scheme of medical device with numbered connections from 1 to 8, showing tubes and valves connected to a main container

  1. Notches on the overbag
  2. Handle
  3. Hole for hanging the bag
  4. Breakable seals
  5. Blind port (used only during manufacturing)
  6. Additive port
  7. Infusion port
  8. Oxygen absorber
  1. Opening the Overbag

Hand holding an auto-injector device on the forearm with arrows indicating the direction of insertion

  • To remove the overbag, hold it in a horizontal position and tear along the notch towards the ports along the top edge (A)
  • Then, simply tear along the container; separate the overbag and discard it along with the oxygen absorber (B).
  1. Mixing

Hand holding a tubular device with connections and valves for nasal oxygen administration

Hands holding a device with tubes and connectors, showing how to pinch the tube to release flow

Hands holding a device with tubes and connectors, preparing for a connection or injection

  • Place the bag on a flat surface.
  • Roll the bag from the hanger part towards the port part, first with the right hand and then applying constant pressure with the left hand until the vertical seals have opened. The vertical peel seals open due to the liquid pressure. The peel seals can also be opened before removing the overbag.

Note:The liquids mix easily even if the horizontal seal remains closed.

Hand holding a device with curved arrows indicating stretching movement on skin and underlying tissue

  • Mix the contents of the three chambers by inverting the bag three times until the components are completely mixed.
  1. Final Preparation:

Hand holding an auto-injector device with exposed needle preparing for subcutaneous administration

  • Place the bag back on a flat surface. Just before injecting additives, break the white additive port by the arrow mark (A).

Note:The additive port membrane is sterile.

  • Hold the base of the additive port. Insert the needle, inject the additives (of known compatibility) through the center of the injection point (B).
  • Mix completely between each addition, inverting the bag three times. Use syringes with 18-23 gauge needles and a maximum length of 40 mm.

Hand holding a device with two buttons and a connected syringe, showing the initial and final position of the injection

  • Just before inserting the infusion set, break the blue infusion port by the arrow mark (A).

Note:The infusion port membrane is sterile.

  • Use non-vented infusion equipment or close the air inlet of the vented equipment.
  • Hold the base of the infusion port.
  • Insert the spike through the infusion port. The spike should be fully inserted to ensure its retention.

Note:The inside of the infusion port is sterile.

  1. Hanging the Bag

Curved needle inserted into the skin with a thread passing through the curve to close a wound

  • Hang the bag by the ring under the hanger
  • Country of registration
  • Active substance
  • Prescription required
    Yes
  • Manufacturer
  • Alternatives to SMOFKABIVEN LOW OSMO PERIPHERAL EMULSION FOR INFUSION
    Dosage form:  INJECTABLE PERFUSION, 3.92 g / 1.26 g / 7.21 g / 3.36 g / 4.2 g / 5.11 g / 2.94 g / 2.8 g / 4.76 g / 5.07 g / 4.06 g / 14.49 g / 0.28 g / 8.05 g / 3.5 g / 200 g
    Active substance:  combinations
    Manufacturer:  Baxter S.L.
    Prescription required
    Dosage form:  INJECTABLE INFUSION, 3.5 g / 200 g / 5.22 g / 1.88 g / 3.92 g / 1.26 g / 7.21 g / 3.36 g / 4.2 g / 5.11 g / 2.94 g / 2.8 g / 662 mg / 1.02 g / 4.76 g / 5.15 g / 5.07 g / 4.06 g / 14.49 g / 0.28 g / 8.05 g
    Active substance:  combinations
    Manufacturer:  Baxter S.L.
    Prescription required
    Dosage form:  INJECTABLE PERFUSION, 4.25 g / 300 g / 5.22 g / 1.54 g / 4.76 g / 1.53 g / 8.76 g / 4.08 g / 5.1 g / 6.2 g / 3.57 g / 3.4 g / 662 mg / 1.02 g / 5.78 g / 5.94 g / 6.16 g / 4.93 g / 17.6 g / 0.34 g / 9.78 g
    Active substance:  combinations
    Manufacturer:  Baxter S.L.
    Prescription required

Online doctors for SMOFKABIVEN LOW OSMO PERIPHERAL EMULSION FOR INFUSION

Discuss questions about SMOFKABIVEN LOW OSMO PERIPHERAL EMULSION FOR INFUSION, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (17)
Doctor

Anastasiia Shalko

Family medicine 13 years exp.

Dr. Anastasiia Shalko is a general practitioner with a background in both paediatrics and general medicine. She graduated from Bogomolets National Medical University in Kyiv and completed her paediatric internship at the P.L. Shupyk National Medical Academy of Postgraduate Education. After working as a paediatrician in Kyiv, she relocated to Spain, where she has been practising general medicine since 2015, providing care for both adults and children.

Her work focuses on urgent, short-term medical concerns – situations where patients need quick guidance, symptom assessment and clear next steps. She helps people understand whether their symptoms require in-person evaluation, home management or a change in treatment. Common reasons for booking an online consultation include:

  • acute respiratory symptoms (cough, sore throat, runny nose, fever)
  • viral illnesses such as colds and seasonal infections
  • gastrointestinal complaints (nausea, diarrhoea, abdominal pain, gastroenteritis)
  • sudden changes in how a child or adult feels
  • questions about existing treatment and whether adjustments are needed
  • renewal of prescriptions when clinically appropriate
Dr. Shalko works specifically with urgent and short-term problems, providing practical recommendations and helping patients determine the safest next step. She explains symptoms clearly, guides patients through decision-making and offers straightforward medical advice for everyday acute issues.

She does not provide long-term management of chronic conditions, ongoing follow-up or comprehensive care plans for complex long-term illnesses. Her consultations are designed for acute symptoms, sudden concerns and situations where timely medical input is important.

With clinical experience in both paediatrics and general medicine, Dr. Shalko confidently supports adults and children. Her communication style is clear, simple and reassuring, helping patients feel informed and supported throughout the consultation.

Camera Book a video appointment
€50
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for SMOFKABIVEN LOW OSMO PERIPHERAL EMULSION FOR INFUSION?
SMOFKABIVEN LOW OSMO PERIPHERAL EMULSION FOR INFUSION requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in SMOFKABIVEN LOW OSMO PERIPHERAL EMULSION FOR INFUSION?
The active ingredient in SMOFKABIVEN LOW OSMO PERIPHERAL EMULSION FOR INFUSION is combinations. This information helps identify medicines with the same composition but different brand names.
Who manufactures SMOFKABIVEN LOW OSMO PERIPHERAL EMULSION FOR INFUSION?
SMOFKABIVEN LOW OSMO PERIPHERAL EMULSION FOR INFUSION is manufactured by Fresenius Kabi España, S.A.U.. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of SMOFKABIVEN LOW OSMO PERIPHERAL EMULSION FOR INFUSION online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether SMOFKABIVEN LOW OSMO PERIPHERAL EMULSION FOR INFUSION is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to SMOFKABIVEN LOW OSMO PERIPHERAL EMULSION FOR INFUSION?
Other medicines with the same active substance (combinations) include CLINIMIX N12G20 SOLUTION FOR INFUSION, CLINIMIX N12G20E SOLUTION FOR INFUSION, CLINIMIX N14G30E SOLUTION FOR INFUSION. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media